Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,685 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Physical activity and breast cancer risk by pathological subtype.
Lope V, Martín M, Castelló A, Casla S, Ruiz A, Baena-Cañada JM, Casas AM, Calvo L, Bermejo B, Muñoz M, Ramos M, de Juan-Ferré A, Jara C, Antón A, Jimeno MÁ, Lluch A, Antolín S, García-Sáenz JÁ, Estévez P, Arriola-Arellano E, Gavilá J, Pérez-Gómez B, Carrasco E, Pollán M; GEICAM, the Spanish Breast Cancer Group. Lope V, et al. Among authors: ruiz a. Gynecol Oncol. 2017 Mar;144(3):577-585. doi: 10.1016/j.ygyno.2016.12.014. Epub 2017 Jan 3. Gynecol Oncol. 2017. PMID: 28057355
Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study.
Castelló A, Martín M, Ruiz A, Casas AM, Baena-Cañada JM, Lope V, Antolín S, Sánchez P, Ramos M, Antón A, Muñoz M, Bermejo B, De Juan-Ferré A, Jara C, Chacón JI, Jimeno MA, Rosado P, Díaz E, Guillem V, Lluch A, Carrasco E, Pérez-Gómez B, Vioque J, Pollán M; EpiGEICAM Researchers. Castelló A, et al. Among authors: ruiz a. PLoS One. 2015 May 15;10(5):e0126096. doi: 10.1371/journal.pone.0126096. eCollection 2015. PLoS One. 2015. PMID: 25978407 Free PMC article.
Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study.
Lope V, Martín M, Castelló A, Ruiz A, Casas AM, Baena-Cañada JM, Antolín S, Ramos-Vázquez M, García-Sáenz JÁ, Muñoz M, Lluch A, de Juan-Ferré A, Jara C, Sánchez-Rovira P, Antón A, Chacón JI, Arcusa A, Jimeno MA, Bezares S, Vioque J, Carrasco E, Pérez-Gómez B, Pollán M. Lope V, et al. Among authors: ruiz a. Sci Rep. 2019 Mar 7;9(1):3904. doi: 10.1038/s41598-019-39346-4. Sci Rep. 2019. PMID: 30846706 Free PMC article.
Adjuvant docetaxel for high-risk, node-negative breast cancer.
Martín M, Seguí MA, Antón A, Ruiz A, Ramos M, Adrover E, Aranda I, Rodríguez-Lescure A, Grosse R, Calvo L, Barnadas A, Isla D, Martinez del Prado P, Ruiz Borrego M, Zaluski J, Arcusa A, Muñoz M, López Vega JM, Mel JR, Munarriz B, Llorca C, Jara C, Alba E, Florián J, Li J, López García-Asenjo JA, Sáez A, Rios MJ, Almenar S, Peiró G, Lluch A; GEICAM 9805 Investigators. Martín M, et al. Among authors: ruiz borrego m, ruiz a. N Engl J Med. 2010 Dec 2;363(23):2200-10. doi: 10.1056/NEJMoa0910320. N Engl J Med. 2010. PMID: 21121833 Free article. Clinical Trial.
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
Martín M, Ruiz A, Ruiz Borrego M, Barnadas A, González S, Calvo L, Margelí Vila M, Antón A, Rodríguez-Lescure A, Seguí-Palmer MA, Muñoz-Mateu M, Dorca Ribugent J, López-Vega JM, Jara C, Espinosa E, Mendiola Fernández C, Andrés R, Ribelles N, Plazaola A, Sánchez-Rovira P, Salvador Bofill J, Crespo C, Carabantes FJ, Servitja S, Chacón JI, Rodríguez CA, Hernando B, Álvarez I, Carrasco E, Lluch A. Martín M, et al. Among authors: ruiz borrego m, ruiz a. J Clin Oncol. 2013 Jul 10;31(20):2593-9. doi: 10.1200/JCO.2012.46.9841. Epub 2013 Jun 3. J Clin Oncol. 2013. PMID: 23733779 Clinical Trial.
Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "El Álamo III" retrospective study.
Márquez-Rodas I, Pollán M, Escudero MJ, Ruiz A, Martín M, Santaballa A, Martínez Del Prado P, Batista N, Andrés R, Antón A, Llombart A, Fernandez Aramburu A, Adrover E, González S, Seguí MA, Calvo L, Lizón J, Rodríguez Lescure Á, Ramón Y Cajal T, Llort G, Jara C, Carrasco E, López-Tarruella S. Márquez-Rodas I, et al. Among authors: ruiz a. PLoS One. 2017 Oct 6;12(10):e0184181. doi: 10.1371/journal.pone.0184181. eCollection 2017. PLoS One. 2017. PMID: 28985233 Free PMC article.
Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.
Martín M, Ruiz A, Muñoz M, Balil A, García-Mata J, Calvo L, Carrasco E, Mahillo E, Casado A, García-Saenz JA, Escudero MJ, Guillem V, Jara C, Ribelles N, Salas F, Soto C, Morales-Vasquez F, Rodríguez CA, Adrover E, Mel JR; Spanish Breast Cancer Research Group (GEICAM) trial. Martín M, et al. Among authors: ruiz a. Lancet Oncol. 2007 Mar;8(3):219-25. doi: 10.1016/S1470-2045(07)70041-4. Lancet Oncol. 2007. PMID: 17329192 Clinical Trial.
Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register.
Puente J, López-Tarruella S, Ruiz A, Lluch A, Pastor M, Alba E, de la Haba J, Ramos M, Cirera L, Antón A, Llombart A, Plazaola A, Fernández-Aramburo A, Sastre J, Díaz-Rubio E, Martin M. Puente J, et al. Among authors: ruiz a. Breast Cancer Res Treat. 2010 Jul;122(2):591-600. doi: 10.1007/s10549-009-0687-4. Epub 2010 Jan 10. Breast Cancer Res Treat. 2010. PMID: 20063196
Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
Llombart-Cussac A, Ruiz A, Antón A, Barnadas A, Antolín S, Alés-Martínez JE, Alvarez I, Andrés R, García Saenz JA, Lao J, Carrasco E, Cámara C, Casas I, Martín M. Llombart-Cussac A, et al. Among authors: ruiz a. Cancer. 2012 Jan 1;118(1):241-7. doi: 10.1002/cncr.26299. Epub 2011 Jun 29. Cancer. 2012. PMID: 21717449 Free article. Clinical Trial.
Efficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in clinical practice.
Gavilá J, Guerrero Á, Climent MÁ, Fernández A, Gozalbo F, Carrascosa M, Camps J, Guillem V, Ruiz A. Gavilá J, et al. Among authors: ruiz a. Int J Clin Oncol. 2015 Jun;20(3):480-9. doi: 10.1007/s10147-014-0727-x. Epub 2014 Jul 11. Int J Clin Oncol. 2015. PMID: 25011497
2,685 results